GAMMA Investing LLC Purchases 27,163 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

GAMMA Investing LLC raised its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 4,965.8% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 27,710 shares of the biotechnology company's stock after purchasing an additional 27,163 shares during the quarter. GAMMA Investing LLC's holdings in Arrowhead Pharmaceuticals were worth $3,530,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in ARWR. Raymond James Financial Inc. acquired a new stake in Arrowhead Pharmaceuticals during the 4th quarter valued at $651,000. BNP Paribas Financial Markets raised its holdings in Arrowhead Pharmaceuticals by 59.5% in the 4th quarter. BNP Paribas Financial Markets now owns 88,029 shares of the biotechnology company's stock valued at $1,655,000 after acquiring an additional 32,841 shares during the period. Empowered Funds LLC acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter worth approximately $268,000. Slate Path Capital LP boosted its holdings in shares of Arrowhead Pharmaceuticals by 7.1% during the fourth quarter. Slate Path Capital LP now owns 5,232,000 shares of the biotechnology company's stock worth $98,362,000 after acquiring an additional 347,000 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $434,000. Institutional investors own 62.61% of the company's stock.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 50,800 shares of the company's stock in a transaction that occurred on Friday, April 11th. The shares were sold at an average price of $11.49, for a total value of $583,692.00. Following the completion of the transaction, the chief executive officer now directly owns 3,921,255 shares in the company, valued at approximately $45,055,219.95. This represents a 1.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 4.30% of the company's stock.

Analyst Ratings Changes

Several analysts recently issued reports on ARWR shares. Citigroup reduced their price target on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. Wall Street Zen upgraded shares of Arrowhead Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Friday, June 6th. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 20th. Chardan Capital reissued a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 13th. Finally, B. Riley reaffirmed a "buy" rating and set a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $43.71.

Arrowhead Pharmaceuticals Price Performance

Shares of Arrowhead Pharmaceuticals stock traded down $0.52 during midday trading on Thursday, hitting $16.22. 1,466,589 shares of the company traded hands, compared to its average volume of 1,530,549. The stock has a market cap of $2.24 billion, a price-to-earnings ratio of -3.14 and a beta of 0.96. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09. The firm's fifty day moving average price is $14.02 and its 200-day moving average price is $17.31. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $9.57 and a 12 month high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $2.81. The company had revenue of $542.71 million for the quarter, compared to analyst estimates of $116.27 million. During the same quarter last year, the company posted ($1.02) earnings per share. As a group, sell-side analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.